Détail de l'auteur
Auteur P. VICKERMAN |
Documents disponibles écrits par cet auteur (37)
Article : Périodique
J. M. KESTEN ; R. AYRES ; J. NEALE ; J. CLARK ; P. VICKERMAN ; M. HICKMAN ; S. REDWOOD |Background: It is recommended that needle and syringe programmes (NSP) distribute low dead space syringes (LDSS) to reduce blood-borne virus transmission. We explored the acceptability of detachable LDSS among people who inject drugs (PWID) and [...]NouveautéArticle : Périodique
L. A. HINES ; A. TRICKEY ; J. LEUNG ; S. LARNEY ; A. PEACOCK ; L. DEGENHARDT ; S. COLLEDGE ; M. HICKMAN ; J. GREBELY ; E. B. CUNNINGHAM ; J. STONE ; K. DUMCHEV ; P. GRIFFITHS ; P. VICKERMAN ; R. P. MATTICK ; M. LYNSKEY |BACKGROUND: Globally, an estimated 15.6 million people inject drugs. We aimed to investigate global variation in the age profile of people who inject drugs (PWID), identify country-level factors associated with age of PWID, and assess the associ[...]Article : Périodique
Aims: To investigate the impact of scaling-up opiate substitution therapy (OST) and high coverage needle and syringe programmes (100%NSP - obtaining more sterile syringes than you inject) on HCV prevalence among injecting drug users (IDUs). De[...]Article : Périodique
BACKGROUND: Interventions such as opiate substitution therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) prevalence among people who inject drugs (PWID). HCV antiviral treatmen[...]Article : Périodique
Studies published by Zule and colleagues have suggested that use of low dead-space syringes (LDSS) instead of high dead-space syringes (HDSS) by injecting drug users (IDUs) could dramatically reduce HIV transmission. However, evidence is limited[...]Article : Périodique
E. HANCOCK ; Z. WARD ; R. AYRES ; J. NEALE ; D. HUSSEY ; J. M. KESTEN ; M. HICKMAN ; P. VICKERMAN |BACKGROUND AND AIMS: Traditional detachable syringes used by people who inject drugs (PWID) retain larger volumes of blood when the plunger is depressed than syringes with fixed needles-referred to as high (HDSS) and low dead space syringes (LDS[...]Article : Périodique
L. PLATT ; J. REED ; S. MINOZZI ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; M. HICKMAN |This is the protocol for a review and there is no abstract. The objectives are as follows: 1. To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people w[...]Article : Périodique
L. DEGENHARDT ; P. WEBB ; S. COLLEDGE-FRISBY ; J. IRELAND ; A. WHEELER ; S. OTTAVIANO ; A. WILLING ; A. KAIROUZ ; E. B. CUNNINGHAM ; B. HAJARIZADEH ; J. LEUNG ; L. T. TRAN ; O. PRICE ; A. PEACOCK ; P. VICKERMAN ; M. FARRELL ; G. J. DORE ; M. HICKMAN ; J. GREBELY |BACKGROUND: People who inject drugs are exposed to various and changing risk environments and are at risk of multiple harms related to injecting drug use (IDU). We aimed to undertake a global systematic review of the prevalence of IDU, key IDU-r[...]Article : Périodique
S. SWEENEY ; Z. WARD ; L. PLATT ; L. GUINNESS ; M. HICKMAN ; V. HOPE ; L. MAHER ; J. IVERSEN ; S. J. HUTCHINSON ; J. SMITH ; R. AYRES ; I. HAINEY ; P. VICKERMAN |AIM: To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. DESIGN: Cost-effectiveness analysis from a National Health Service (NHS)/healt[...]Article : Périodique
V. HOPE ; J. KIMBER ; P. VICKERMAN ; M. HICKMAN ; F. NCUBE |BACKGROUND: Injection site infections among injecting drug users (IDUs) have been associated with serious morbidity and health service costs in North America. This study explores the frequency, factors and costs associated with injection site in[...]Article : Périodique
S. COLLEDGE ; J. LEUNG ; S. LARNEY ; A. PEACOCK ; J. GREBELY ; M. HICKMAN ; E. CUNNINGHAM ; A. TRICKEY ; J. STONE ; P. VICKERMAN ; L. DEGENHARDT |BACKGROUND: People who inject drugs (PWID) do so at varying frequencies. More frequent injecting is associated with skin and soft tissue infection, blood borne viruses, and overdose. The aims of this review are to estimate the prevalence of inje[...]Article : Périodique
S. COLLEDGE-FRISBY ; S. OTTAVIANO ; P. WEBB ; J. GREBELY ; A. WHEELER ; E. B. CUNNINGHAM ; B. HAJARIZADEH ; J. LEUNG ; A. PEACOCK ; P. VICKERMAN ; M. FARRELL ; G. J. DORE ; M. HICKMAN ; L. DEGENHARDT |BACKGROUND: Harm reduction and treatment programmes are essential for reducing harms for people who inject drugs (PWID). We aimed to update estimates from a 2017 review of global coverage of needle and syringe exchange programmes (NSPs), opioid [...]Article : Périodique
J. LEUNG ; A. PEACOCK ; S. COLLEDGE ; J. GREBELY ; E. B. CUNNINGHAM ; M. HICKMAN ; P. VICKERMAN ; J. STONE ; A. TRICKEY ; K. DUMCHEV ; M. LYNSKEY ; L. HINES ; P. GRIFFITHS ; R. P. MATTICK ; L. DEGENHARDT ; S. LARNEY |BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. MET[...]Article : Périodique
L. DEGENHARDT ; J. GREBELY ; J. STONE ; M. HICKMAN ; P. VICKERMAN ; B. D. L. MARSHALL ; J. BRUNEAU ; F. L. ALTICE ; G. HENDERSON ; A. RAHIMI-MOVAGHAR ; S. LARNEY |We summarise the evidence for medicinal uses of opioids, harms related to the extramedical use of, and dependence on, these drugs, and a wide range of interventions used to address these harms. The Global Burden of Diseases, Injuries, and Risk F[...]Article : Périodique
L. DEGENHARDT ; A. PEACOCK ; S. COLLEDGE ; J. LEUNG ; J. GREBELY ; P. VICKERMAN ; J. STONE ; E. B. CUNNINGHAM ; A. TRICKEY ; K. DUMCHEV ; M. LYNSKEY ; P. GRIFFITHS ; R. P. MATTICK ; M. HICKMAN ; S. LARNEY |Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among[...]Article : Périodique
S. LARNEY ; A. PEACOCK ; J. LEUNG ; S. COLLEDGE ; M. HICKMAN ; P. VICKERMAN ; J. GREBELY ; K. V. DUMCHEV ; P. GRIFFITHS ; L. HINES ; E. B. CUNNINGHAM ; R. P. MATTICK ; M. LYNSKEY ; J. MARSDEN ; J. STRANG ; L. DEGENHARDT |Background: People who inject drugs (PWID) are a key population affected by the global HIV and hepatitis C virus (HCV) epidemics. HIV and HCV prevention interventions for PWID include needle and syringe programmes (NSP), opioid substitution ther[...]Article : Périodique
J. GREBELY ; S. LARNEY ; A. PEACOCK ; S. COLLEDGE ; J. LEUNG ; M. HICKMAN ; P. VICKERMAN ; S. BLACH ; E. B. CUNNINGHAM ; K. DUMCHEV ; M. LYNSKEY ; J. STONE ; A. TRICKEY ; H. RAZAVI ; R. P. MATTICK ; M. FARRELL ; G. J. DORE ; L. DEGENHARDT |BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with[...]Article : Périodique
L. WIESSING ; M. FERRI ; B. GRADY ; M. KANTZANOU ; I. SPERLE ; K. J. CULLEN ; EMCDDA DRID Group ; A. HATZAKIS ; M. PRINS ; P. VICKERMAN ; J. V. LAZARUS ; V. D. HOPE ; C. MATHEI |Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of informati[...]Article : Périodique
Z. WARD ; L. PLATT ; S. SWEENEY ; V. D. HOPE ; L. MAHER ; S. HUTCHINSON ; N. PALMATEER ; J. SMITH ; N. CRAINE ; A. TAYLOR ; N. MARTIN ; R. AYRES ; J. DILLON ; M. HICKMAN ; P. VICKERMAN |Aims: To estimate the impact of existing high-coverage needle and syringe provision (HCNSP, defined as obtaining more than one sterile needle and syringe per injection reported) and opioid substitution therapy (OST) on hepatitis C virus (HCV) tr[...]Article : Périodique
Aims: To assess systematically the risk of HIV acquisition by type of drug injected across different settings. Methods: A systematic review and meta-analysis were conducted. Databases were searched for studies of HIV incidence in people who in[...]Article : Périodique
L. T. TRAN ; A. PEACOCK ; S. COLLEDGE ; S. MEMEDOVIC ; J. GREBELY ; J. LEUNG ; S. LARNEY ; A. TRICKEY ; J. STONE ; P. VICKERMAN ; M. HICKMAN ; L. DEGENHARDT |Background: Injecting risk behaviour, such as receptive sharing of injecting equipment and/or re-using one's equipment, is associated with bloodborne virus transmission and infections in people who inject drugs (PWID). We aimed to estimate preva[...]Article : Périodique
E. B. CUNNINGHAM ; A. WHEELER ; B. HAJARIZADEH ; C. E. FRENCH ; R. ROCHE ; A. D. MARSHALL ; G. FONTAINE ; A. CONWAY ; S. BAJIS ; B. M. VALENCIA ; J. PRESSEAU ; J. W. WARD ; L. DEGENHARDT ; G. J. DORE ; M. HICKMAN ; P. VICKERMAN ; J. GREBELY |Background: With the advent of direct acting antiviral (DAA) therapies for the treatment of hepatitis C virus (HCV), the World Health Organization recommended a goal to eliminate HCV as a public health threat globally by 2030. With the majority [...]Article : Périodique
N. PALMATEER ; V. HAMILL ; A. BERGENSTROM ; H. BLOOMFIELD ; L. GORDON ; J. STONE ; H. FRASER ; T. SEYLER ; Y. DUAN ; R. TRAN ; K. TRAYNER ; C. BIGGAM ; S. SMITH ; P. VICKERMAN ; M. HICKMAN ; S. HUTCHINSON |Background: Hepatitis C virus (HCV) and HIV remain prevalent among people who inject drugs (PWID) and transmission is usually associated with injecting risk behaviour (IRB). We update a 2011 review of reviews (RoR) to assess the latest evidence [...]Article : Périodique
H. FRASER ; N. K. MARTIN ; H. BRUMMER-KORVENKONTIO ; P. CARRIERI ; O. DALGARD ; J. DILLON ; D. GOLDBERG ; S. HUTCHINSON ; M. JAUFFRET-ROUSTIDE ; M. KABERG ; A. A. MATSER ; M. MATICIC ; H. MIDGARD ; V. MRAVCIK ; A. OVREHUS ; M. PRINS ; J. REIMER ; G. ROBAEYS ; B. SCHULTE ; D. K. VAN SANTEN ; R. ZIMMERMANN ; P. VICKERMAN ; M. HICKMAN |BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opio[...]Article : Périodique
J. STONE ; N. K. MARTIN ; M. HICKMAN ; S. J. HUTCHINSON ; E. ASPINALL ; A. TAYLOR ; A. MUNRO ; K. DUNLEAVY ; E. PETERS ; P. BRAMLEY ; P. C. HAYES ; D. J. GOLDBERG ; P. VICKERMAN |Background and Aims: People who inject drugs (PWID) experience high incarceration rates, and previous incarceration is associated with elevated hepatitis C virus (HCV) transmission risk. In Scotland, national survey data indicate lower HCV incid[...]Article : Périodique
L. WIESSING ; M. FERRI ; V. BELACKOVA ; P. CARRIERI ; S. R. FRIEDMAN ; C. FOLCH ; K. DOLAN ; B. GALVIN ; P. VICKERMAN ; J. V. LAZARUS ; V. MRAVCIK ; M. KRETZSCHMAR ; V. SYPSA ; A. SARASA-RENEDO ; A. UUSKULA ; D. PARASKEVIS ; L. MENDAO ; D. ROSSI ; N. VAN GELDER ; L. MITCHESON ; L. PAOLI ; C. DIAZ GOMEZ ; M. MILHET ; N. DASCALU ; J. KNIGHT ; G. HAY ; E. KALAMARA ; R. SIMON ; C. M. COMISKEY ; C. ROSSI ; P. GRIFFITHS ; EUBEST working group |Background and aims: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the histori[...]Article : Périodique
L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN |Aims: To estimate the effects of needle and syringe programmes (NSP) and opioid substitution therapy (OST), alone or in combination, for preventing acquisition of hepatitis C virus (HCV) in people who inject drugs (PWID). Methods: Systematic re[...]Article : Périodique
L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN |Review question: We examine research on the effect of needle syringe programmes (NSP) and opioid substitution treatment (OST) in reducing the risk of becoming infected with the hepatitis C virus. Background: There are around 114.9 million peopl[...]Article : Périodique
G. J. MACARTHUR ; S. MINOZZI ; N. MARTIN ; P. VICKERMAN ; S. DEREN ; J. BRUNEAU ; L. DEGENHARDT ; M. HICKMAN |Objective: To quantify the effect of opiate substitution treatment in relation to HIV transmission among people who inject drugs. Design: Systematic review and meta-analysis of prospective published and unpublished observational studies. Data [...]Rapport
G. W. SHORTER ; P. E. MCKENNA-PLUMLEY ; K. B. D. CAMPBELL ; J. R. KEEMINK ; B. D. SCHER ; S. CUTTER ; Z. KHADJESARI ; A. STEVENS ; A. ARTENIE ; P. VICKERMAN ; P. BOLAND ; N. M. MILLER ; A. O. CAMPBELL | London : Drug Science | 2023This rapid review on overdose prevention centres (OPCs) aims to collate and summarise existing evidence. It describes the impact of OPCs on individuals who use drugs, communities, and public health. OPCs are community facilities which provide a [...]Article : Périodique
L. PLATT ; P. EASTERBROOK ; E. GOWER ; B. MCDONALD ; K. SABIN ; C. McGOWAN ; I. YANNY ; H. RAZAVI ; P. VICKERMAN |Background: At global level, there are 37 million people infected with HIV and 115 million people with antibodies to hepatitis C virus (HCV). Little is known about the extent of HIV-HCV co-infection. We sought to characterise the epidemiology an[...]Article : Périodique
L. DEGENHARDT ; B. MATHERS ; P. VICKERMAN ; T. RHODES ; C. LATKIN ; M. HICKMAN |HIV can spread rapidly between people who inject drugs (through injections and sexual transmission), and potentially the virus can pass to the wider community (by sexual transmission). Here, we summarise evidence on the effectiveness of individu[...]Article : Périodique
J. CSETE ; A. KAMARULZAMAN ; M. KAZATCHKINE ; F. ALTICE ; M. BALICKI ; J. BUXTON ; J. CEPEDA ; M. COMFORT ; E. GOOSBY ; J. GOULAO ; C. HART ; T. KERR ; A. M. LAJOUS ; S. LEWIS ; N. MARTIN ; D. MEJIA ; A. CAMACHO ; D. MATHIESON ; I. OBOT ; A. OGUNROMBI ; S. SHERMAN ; J. STONE ; N. VALLATH ; P. VICKERMAN ; T. ZABRANSKY ; C. BEYRER |ENGLISH: In September, 2015, the member states of the UN endorsed Sustainable Development Goals (SDGs) for 2030, which aspire to human-rights-centred approaches to ensuring the health and wellbeing of all people. The SDGs embody both the UN Cha[...]Article : Périodique
H. L. MILLS ; C. COLIJN ; P. VICKERMAN ; D. LESLIE ; V. HOPE ; M. HICKMAN |Background: A 2006 respondent driven sampling (RDS) survey of injecting drug users (IDUs) in Bristol, UK, estimated 40 per 100 person years HCV incidence but in 2009 another RDS survey estimated only 10 per 100 person years incidence amongst the[...]Article : Périodique
R. CORNISH ; J. MACLEOD ; J. STRANG ; P. VICKERMAN ; M. HICKMAN |Objective To investigate the effect of opiate substitution treatment at the beginning and end of treatment and according to duration of treatment. Design Prospective cohort study. Setting UK General Practice Research Database Participants Pri[...]Article : Périodique
H. FRASER ; J. ZIBBELL ; T. HOERGER ; S. HARIRI ; C. VELLOZZI ; N. K. MARTIN ; A. H. KRAL ; M. HICKMAN ; J. W. WARD ; P. VICKERMAN |Background and aims: Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection among people who inject drugs (PWID) in rural settings of the United States. We determined the required scale-up of HCV treat[...]Périodique
The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus
KUMARANAYAKE L. ; P. VICKERMAN ; D. WALKER ; SAMOSHKIN S. ; ROMANTZOV V. ; EMELYANOVA Z. ; ZVIAGIN V. ; C. WATTS | 2004ENGLISH : Aim. To undertake a cost-effectiveness analysis of a harm reduction and HIV prevention project for injecting drug users (IDUs) in Eastern Europe. Economic evaluation methods were adapted to consider the effect of an 8-month financing[...]